Interleukin-2: Difference between revisions
Jump to navigation
Jump to search
imported>Howard C. Berkowitz No edit summary |
imported>Howard C. Berkowitz No edit summary |
||
| Line 12: | Line 12: | ||
| url = http://www.medscape.com/druginfo/monograph?cid=med&drugid=16389&drugname=Thalidomide+Oral&monotype=monograph&secid=8 | | url = http://www.medscape.com/druginfo/monograph?cid=med&drugid=16389&drugname=Thalidomide+Oral&monotype=monograph&secid=8 | ||
| title = Monograph: Thalidomide — Pharmacology | | title = Monograph: Thalidomide — Pharmacology | ||
| publisher = American Society of Health System Pharmacists/Medscape | | publisher = American Society of Health System Pharmacists/Medscape | ||
}}</ref> | }}</ref> | ||
==References== | ==References== | ||
{{reflist}} | {{reflist|2}} | ||
Revision as of 00:09, 19 August 2010
Interleukin-2 is an interleukin generated by T4 helper lymphocytes. It induces DNA synthesis in naive lymphocytes. Other terms include Lymphocyte Mitogenic Factor, T-Cell Growth Factor, Thymocyte Stimulating Factor and T-Cell Stimulating Factor.[1]
The gene expresses when stimulated by human T-cell leukemia virus Type 1.[2]
Thalidomide has a costimulatory or adjuvant effect on T-lymphocytes resulting in increased T-cell proliferation and increased production of interleukin-2 and interferon gamma.[3]
References
- ↑ Anonymous (2024), Interleukin-2 (English). Medical Subject Headings. U.S. National Library of Medicine.
- ↑ Jun-ichiro Inoue et al. (1986), "Induction of interleukin 2 receptor gene expression by p40x encoded by human T-cell leukemia virus type 1", EMBO Journal 5 (11): 2883-2888
- ↑ Monograph: Thalidomide — Pharmacology, American Society of Health System Pharmacists/Medscape